RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/34635651http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/34635651http://www.w3.org/2000/01/rdf-schema#comment"Abnormal activation of epidermal growth factor receptor (EGFR) drives non-small cell lung cancer (NSCLC) development. EGFR mutations-mediated resistance to tyrosine-kinase inhibitors (TKIs) is a major hurdle for NSCLC treatment. Here, we show that F-box protein FBXL2 targets EGFR and EGFR TKI-resistant mutants for proteasome-mediated degradation, resulting in suppression of EGFR-driven NSCLC growth. Reduced FBXL2 expression is associated with poor clinical outcomes of NSCLC patients. Furthermore, we show that glucose-regulated protein 94 (Grp94) protects EGFR from degradation via blockage of FBXL2 binding to EGFR. Moreover, we have identified nebivolol, a clinically used small molecule inhibitor, that can upregulate FBXL2 expression to inhibit EGFR-driven NSCLC growth. Nebivolol in combination with osimertinib or Grp94-inhibitor-1 exhibits strong inhibitory effects on osimertinib-resistant NSCLC. Together, this study demonstrates that the FBXL2-Grp94-EGFR axis plays a critical role in NSCLC development and suggests that targeting FBXL2-Grp94 to destabilize EGFR may represent a putative therapeutic strategy for TKI-resistant NSCLC."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.org/dc/terms/identifier"doi:10.1038/s41467-021-26222-x"xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Chen H."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Cao Y."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Ding L."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Guo R."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Gao Y."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"He Y."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Hu Q."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Fu M."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Li F."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Liu Y."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Li L."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Li Z."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Luo Y."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Li Y."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Li R."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Niu M."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Dong B."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Qi S."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Yang J."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Zhang Y."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Yu S."xsd:string
http://purl.uniprot.org/citations/34635651http://purl.uniprot.org/core/author"Wang L."xsd:string